F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.